Statement: Zantac (Ranitidine) Litigation – Gross Case
Statement: Zantac (Ranitidine) Litigation – Gross Case
GSK plc (LSE/NYSE: GSK) has reached a confidential settlement with Martin Gross resolving the case he filed in Illinois state court. GSK does not admit any liability in this settlement. The case will now be dismissed as to GSK.
GSK plc（LSE/NYSE: GSK）已與馬丁·格羅斯達成保密和解，解決了他在伊利諾伊州法院提起的案件。GSK在此和解中不承認任何責任。該案件現已對GSK做出駁回裁定。
Following the 16 epidemiological studies looking at human data regarding the use of ranitidine, the scientific consensus is that there is no consistent or reliable evidence that ranitidine increases the risk of any cancer.
在對人類有關雷尼替丁使用的16項流行病學研究後，科學共識是並沒有一致或可靠的證據表明雷尼替丁增加任何癌症的風險。
GSK will continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
GSK將繼續積極捍衛自己，並根據公司和股東的最佳利益管理此訴訟。
About GSK
關於GSK
GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.
GSK是一家全球生物製藥公司，以聯合科學、技術和人才共同掌控疾病爲宗旨。了解更多請訪問gsk.com.
Cautionary statement regarding forward-looking statements
關於前瞻性聲明的警告聲明
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D "Risk factors" in GSK's Annual Report on Form 20-F for 2023, and GSK's Q1 Results for 2024.
GSK提醒投資者，GSK所作出的任何前瞻性聲明或預測，包括本公告所作出的前瞻性聲明或預測，均受到風險和不確定性的影響，可能導致實際結果與預期有所不同。這樣的因素包括，但不限於，GSK2023年的年報20-F項目3.D“風險因素”和GSK2024年第一季度的業績。
譯文內容由第三人軟體翻譯。